Farletuzumab Shows Limited Efficacy in Relapsed Ovarian Cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, April 07, 2016

Farletuzumab Shows Limited Efficacy in Relapsed Ovarian Cancer

cancer news
Maintenance farletuzumab following chemotherapy in combination with farletuzumab did not improve progression-free survival (PFS) for women with recurrent ovarian cancer, according to results from a study published in the Journal of Clinical Oncology.1
However, this global, multicenter, phase 3 study showed that risk for progression was reduced by 51% in a subset of patients with CA-125 not more than 3 times the upper limit of normal (ULN).
“These observations provide a dose-efficacy relationship for farletuzumab, and hence, proof of principle,” corresponding author Ignace Vergote, MD, chairman of the Leuven Cancer Institute, University Hospital Leuven, Belgium, told Cancer Therapy Advisor.
For women with epithelial ovarian cancer that has relapsed following initial response to a platinum-based regimen, treatment options are limited to further chemotherapy-based regimens.


Post a Comment

Your comments?